JP5596026B2 - チオフェン又はチアゾール誘導体及びpi3k阻害剤としてのそれらの使用 - Google Patents
チオフェン又はチアゾール誘導体及びpi3k阻害剤としてのそれらの使用 Download PDFInfo
- Publication number
- JP5596026B2 JP5596026B2 JP2011514600A JP2011514600A JP5596026B2 JP 5596026 B2 JP5596026 B2 JP 5596026B2 JP 2011514600 A JP2011514600 A JP 2011514600A JP 2011514600 A JP2011514600 A JP 2011514600A JP 5596026 B2 JP5596026 B2 JP 5596026B2
- Authority
- JP
- Japan
- Prior art keywords
- membered
- optionally substituted
- nitrogen
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*CC(CO)Nc1c(C)c(*)c(C2=N***2)[s]1 Chemical compound C*CC(CO)Nc1c(C)c(*)c(C2=N***2)[s]1 0.000 description 23
- DZRKPIICYODVAO-UHFFFAOYSA-N CCOC(c([s]c(SC)c1C#N)c1I)=O Chemical compound CCOC(c([s]c(SC)c1C#N)c1I)=O DZRKPIICYODVAO-UHFFFAOYSA-N 0.000 description 1
- SYDDCXMMTMOPIS-UHFFFAOYSA-N CCS(C)c([s]c(C(N)=O)c1I)c1C#N Chemical compound CCS(C)c([s]c(C(N)=O)c1I)c1C#N SYDDCXMMTMOPIS-UHFFFAOYSA-N 0.000 description 1
- RLLYIKSEIMDBCR-UHFFFAOYSA-N CSc([s]c(C(N)=O)c1I)c1C#N Chemical compound CSc([s]c(C(N)=O)c1I)c1C#N RLLYIKSEIMDBCR-UHFFFAOYSA-N 0.000 description 1
- XQJYHEHIXVFDIS-UHFFFAOYSA-N Cc1ccc(C[Cl]=O)c(Cl)c1 Chemical compound Cc1ccc(C[Cl]=O)c(Cl)c1 XQJYHEHIXVFDIS-UHFFFAOYSA-N 0.000 description 1
- QGKBWMKHMCWYHW-UHFFFAOYSA-N N#CC(C(c(c(Cl)c1)ccc1Cl)=O)C(N1CCC2=CC2CC1)=S Chemical compound N#CC(C(c(c(Cl)c1)ccc1Cl)=O)C(N1CCC2=CC2CC1)=S QGKBWMKHMCWYHW-UHFFFAOYSA-N 0.000 description 1
- AUZPMUJGZZSMCP-UHFFFAOYSA-N N#CCC(N1CCOCC1)=O Chemical compound N#CCC(N1CCOCC1)=O AUZPMUJGZZSMCP-UHFFFAOYSA-N 0.000 description 1
- VLMZXRFDZPDWQU-UHFFFAOYSA-N N#CCC(N1CCOCC1)=S Chemical compound N#CCC(N1CCOCC1)=S VLMZXRFDZPDWQU-UHFFFAOYSA-N 0.000 description 1
- VXTYIKXKNTWGFZ-UHFFFAOYSA-N N#Cc1c(N2CCOCC2)[s]c(-c2cnc[nH]2)c1-c(ccc(Cl)c1)c1Cl Chemical compound N#Cc1c(N2CCOCC2)[s]c(-c2cnc[nH]2)c1-c(ccc(Cl)c1)c1Cl VXTYIKXKNTWGFZ-UHFFFAOYSA-N 0.000 description 1
- MXDXVJFDWBKXLK-UHFFFAOYSA-N NC(c([s]c(N1CC(CO)CCC1)c1N)c1-c(ccc(C=[IH])c1)c1Cl)=O Chemical compound NC(c([s]c(N1CC(CO)CCC1)c1N)c1-c(ccc(C=[IH])c1)c1Cl)=O MXDXVJFDWBKXLK-UHFFFAOYSA-N 0.000 description 1
- UTYCGBVJQHLJOX-UHFFFAOYSA-N Nc1c(N2CC(CO)CCC2)[s]c(-c2nnc[nH]2)c1-c(ccc(Cl)c1)c1Cl Chemical compound Nc1c(N2CC(CO)CCC2)[s]c(-c2nnc[nH]2)c1-c(ccc(Cl)c1)c1Cl UTYCGBVJQHLJOX-UHFFFAOYSA-N 0.000 description 1
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N OB(c(c(Cl)c1)ccc1Cl)O Chemical compound OB(c(c(Cl)c1)ccc1Cl)O QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 1
- VLAZLCVSFAYIIL-UHFFFAOYSA-N OCC1OCCNC1 Chemical compound OCC1OCCNC1 VLAZLCVSFAYIIL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13248408P | 2008-06-19 | 2008-06-19 | |
| US61/132,484 | 2008-06-19 | ||
| PCT/US2009/003607 WO2009154741A1 (en) | 2008-06-19 | 2009-06-17 | Thiophene or thiazole derivatives and their use as pi3k inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524904A JP2011524904A (ja) | 2011-09-08 |
| JP2011524904A5 JP2011524904A5 (OSRAM) | 2012-10-18 |
| JP5596026B2 true JP5596026B2 (ja) | 2014-09-24 |
Family
ID=41010579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514600A Active JP5596026B2 (ja) | 2008-06-19 | 2009-06-17 | チオフェン又はチアゾール誘導体及びpi3k阻害剤としてのそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8183240B2 (OSRAM) |
| EP (1) | EP2313399B1 (OSRAM) |
| JP (1) | JP5596026B2 (OSRAM) |
| KR (1) | KR20110018451A (OSRAM) |
| CN (1) | CN102066365A (OSRAM) |
| AU (1) | AU2009260782B2 (OSRAM) |
| BR (1) | BRPI0914223A2 (OSRAM) |
| CA (1) | CA2727069A1 (OSRAM) |
| CL (1) | CL2010001474A1 (OSRAM) |
| CO (1) | CO6331431A2 (OSRAM) |
| CR (1) | CR20110032A (OSRAM) |
| EA (1) | EA201170052A1 (OSRAM) |
| ES (1) | ES2491522T3 (OSRAM) |
| GE (1) | GEP20125650B (OSRAM) |
| IL (1) | IL210055A0 (OSRAM) |
| MA (1) | MA32468B1 (OSRAM) |
| MX (1) | MX2010014125A (OSRAM) |
| NZ (1) | NZ589844A (OSRAM) |
| UA (1) | UA106206C2 (OSRAM) |
| WO (1) | WO2009154741A1 (OSRAM) |
| ZA (1) | ZA201008875B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| AU2009260782B2 (en) * | 2008-06-19 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Thiophene or thiazole derivatives and their use as PI3K inhibitors |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) * | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| WO2012021615A1 (en) * | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| UY33554A (es) | 2010-08-11 | 2012-02-29 | Millennium Pharm Inc | Heteroarilos y usos de los mismos |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP5726635B2 (ja) | 2010-08-25 | 2015-06-03 | 株式会社Nttドコモ | マルチモードフロントエンド回路 |
| BR112013009166A2 (pt) | 2010-10-13 | 2016-07-26 | Millennium Pharm Inc | heteroarilas e uso das mesmas. |
| CN102503930B (zh) * | 2011-10-28 | 2014-07-02 | 浙江大学 | 3,4,5,-三取代氨基噻吩类化合物及其制备和用途 |
| ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
| WO2013096642A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| IN2014DN06898A (OSRAM) | 2012-03-14 | 2015-05-15 | Salk Inst For Biological Studi | |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
| RU2016136091A (ru) * | 2014-02-14 | 2018-03-19 | Дзе Юниверсити Оф Бритиш Коламбиа | Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| WO2020261144A1 (en) * | 2019-06-28 | 2020-12-30 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
| CN110759900B (zh) * | 2019-10-25 | 2021-07-30 | 沈阳药科大学 | 噻吩类化合物的制备方法和用途 |
| PE20221327A1 (es) | 2019-12-20 | 2022-09-09 | Bayer Ag | Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD275870A1 (de) | 1988-09-27 | 1990-02-07 | Univ Leipzig | Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen |
| CA2565965A1 (en) * | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| US20090076009A1 (en) | 2006-05-03 | 2009-03-19 | Arnould Jean-Claude Retired | Thiazole derivatives and their use as anti-tumour agents |
| MX2009002046A (es) * | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
| CA2704711C (en) * | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| EP2250160B1 (en) * | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| AU2009260782B2 (en) * | 2008-06-19 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Thiophene or thiazole derivatives and their use as PI3K inhibitors |
-
2009
- 2009-06-17 AU AU2009260782A patent/AU2009260782B2/en not_active Ceased
- 2009-06-17 GE GEAP200912065A patent/GEP20125650B/en unknown
- 2009-06-17 CN CN2009801230046A patent/CN102066365A/zh active Pending
- 2009-06-17 MX MX2010014125A patent/MX2010014125A/es active IP Right Grant
- 2009-06-17 CA CA2727069A patent/CA2727069A1/en not_active Abandoned
- 2009-06-17 EP EP09767054.1A patent/EP2313399B1/en active Active
- 2009-06-17 ES ES09767054.1T patent/ES2491522T3/es active Active
- 2009-06-17 KR KR1020117001175A patent/KR20110018451A/ko not_active Ceased
- 2009-06-17 EA EA201170052A patent/EA201170052A1/ru unknown
- 2009-06-17 BR BRPI0914223A patent/BRPI0914223A2/pt not_active IP Right Cessation
- 2009-06-17 UA UAA201100563A patent/UA106206C2/ru unknown
- 2009-06-17 NZ NZ589844A patent/NZ589844A/xx not_active IP Right Cessation
- 2009-06-17 JP JP2011514600A patent/JP5596026B2/ja active Active
- 2009-06-17 WO PCT/US2009/003607 patent/WO2009154741A1/en not_active Ceased
- 2009-06-17 US US12/456,455 patent/US8183240B2/en active Active
-
2010
- 2010-12-09 ZA ZA2010/08875A patent/ZA201008875B/en unknown
- 2010-12-16 IL IL210055A patent/IL210055A0/en unknown
- 2010-12-17 CL CL2010001474A patent/CL2010001474A1/es unknown
- 2010-12-23 CO CO10161488A patent/CO6331431A2/es active IP Right Grant
-
2011
- 2011-01-13 MA MA33511A patent/MA32468B1/fr unknown
- 2011-01-17 CR CR20110032A patent/CR20110032A/es not_active Application Discontinuation
-
2012
- 2012-04-18 US US13/449,341 patent/US8440664B2/en active Active
-
2013
- 2013-04-01 US US13/854,409 patent/US20130217689A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2313399A1 (en) | 2011-04-27 |
| WO2009154741A8 (en) | 2010-03-25 |
| CL2010001474A1 (es) | 2011-04-29 |
| UA106206C2 (ru) | 2014-08-11 |
| ZA201008875B (en) | 2012-02-29 |
| EP2313399B1 (en) | 2014-05-28 |
| US20130217689A1 (en) | 2013-08-22 |
| US8440664B2 (en) | 2013-05-14 |
| ES2491522T3 (es) | 2014-09-08 |
| AU2009260782B2 (en) | 2014-12-11 |
| EA201170052A1 (ru) | 2011-06-30 |
| CO6331431A2 (es) | 2011-10-20 |
| CA2727069A1 (en) | 2009-12-23 |
| JP2011524904A (ja) | 2011-09-08 |
| CN102066365A (zh) | 2011-05-18 |
| MA32468B1 (fr) | 2011-07-03 |
| BRPI0914223A2 (pt) | 2019-09-24 |
| US8183240B2 (en) | 2012-05-22 |
| WO2009154741A1 (en) | 2009-12-23 |
| MX2010014125A (es) | 2011-02-24 |
| US20120202812A1 (en) | 2012-08-09 |
| IL210055A0 (en) | 2011-02-28 |
| AU2009260782A1 (en) | 2009-12-23 |
| GEP20125650B (en) | 2012-09-25 |
| US20100075951A1 (en) | 2010-03-25 |
| KR20110018451A (ko) | 2011-02-23 |
| NZ589844A (en) | 2012-11-30 |
| CR20110032A (es) | 2011-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5596026B2 (ja) | チオフェン又はチアゾール誘導体及びpi3k阻害剤としてのそれらの使用 | |
| EP2250160B1 (en) | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors | |
| US8859768B2 (en) | Heteroaryls and uses thereof | |
| WO2013096637A1 (en) | Heteroaryls and uses thereof | |
| US9062038B2 (en) | Heteroaryls and uses thereof | |
| US8796314B2 (en) | Heteroaryls and uses thereof | |
| HK1157327B (en) | Thiophene or thiazole derivatives and their use as pi3k inhibitors | |
| HK1157327A (en) | Thiophene or thiazole derivatives and their use as pi3k inhibitors | |
| AU2013203960A1 (en) | Thiophene or thiazole derivatives and their use as PI3K inhibitors | |
| HK40087839A (zh) | 哌嗪环状脲 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131108 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140109 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140701 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140806 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5596026 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |